PT858804E - Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose - Google Patents

Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose

Info

Publication number
PT858804E
PT858804E PT98101081T PT98101081T PT858804E PT 858804 E PT858804 E PT 858804E PT 98101081 T PT98101081 T PT 98101081T PT 98101081 T PT98101081 T PT 98101081T PT 858804 E PT858804 E PT 858804E
Authority
PT
Portugal
Prior art keywords
treatment
crisposporidios
rifaximine
diarrhea
drug
Prior art date
Application number
PT98101081T
Other languages
English (en)
Portuguese (pt)
Inventor
Antonella Ferrieri
Patrizio Ferrari
Pietro Caramello
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of PT858804E publication Critical patent/PT858804E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PT98101081T 1997-02-14 1998-01-22 Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose PT858804E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (1)

Publication Number Publication Date
PT858804E true PT858804E (pt) 2002-10-31

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98101081T PT858804E (pt) 1997-02-14 1998-01-22 Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose

Country Status (12)

Country Link
US (1) US5886002A (zh)
EP (1) EP0858804B1 (zh)
JP (1) JP4848083B2 (zh)
KR (1) KR100436243B1 (zh)
CN (1) CN1115146C (zh)
AT (1) ATE218342T1 (zh)
DE (1) DE69805672T2 (zh)
DK (1) DK0858804T3 (zh)
ES (1) ES2178048T3 (zh)
HU (1) HU224592B1 (zh)
IT (1) IT1290679B1 (zh)
PT (1) PT858804E (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
JP2006525329A (ja) * 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸類
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
JP5844961B2 (ja) * 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
RU2011116400A (ru) * 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
LT3628319T (lt) 2008-10-02 2024-03-25 Salix Pharmaceuticals, Inc. Hepatinės encefalopatijos gydymas rifaksiminu
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9211258B2 (en) * 2010-03-10 2015-12-15 Lupin Limited Rifaximin ready-to-use suspension
MX2013002802A (es) 2010-09-13 2013-06-03 Cipla Ltd Composicion farmaceutica.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
US20180021297A1 (en) * 2015-02-26 2018-01-25 Jaguar Health, Inc. Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animals
CA2988930A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
EP3525825B1 (en) 2016-10-14 2024-03-20 Cipla Limited Pharmaceutical compositions comprising rifaximin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
DK0858804T3 (da) 2002-07-08
IT1290679B1 (it) 1998-12-10
ITBO970064A1 (it) 1998-08-14
ITBO970064A0 (it) 1997-02-14
KR100436243B1 (ko) 2004-08-25
JPH10226645A (ja) 1998-08-25
EP0858804B1 (en) 2002-06-05
ATE218342T1 (de) 2002-06-15
HU9800115D0 (en) 1998-03-30
EP0858804A1 (en) 1998-08-19
HUP9800115A3 (en) 2000-04-28
DE69805672D1 (de) 2002-07-11
KR19980071348A (ko) 1998-10-26
CN1214244A (zh) 1999-04-21
ES2178048T3 (es) 2002-12-16
HU224592B1 (hu) 2005-11-28
DE69805672T2 (de) 2003-01-23
US5886002A (en) 1999-03-23
CN1115146C (zh) 2003-07-23
JP4848083B2 (ja) 2011-12-28
HUP9800115A1 (hu) 1999-06-28

Similar Documents

Publication Publication Date Title
PT858804E (pt) Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE60042153D1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
BR0107333A (pt) Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares
DE69830503D1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
BR0009718A (pt) Processo de tratamento
FI954131A (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
GB0111186D0 (en) Novel compounds
ES2195397T3 (es) Quinazolin-2,4-dionas sustituidas en posicion 7 utiles como agentes antibacterianos.
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
YU13301A (sh) Muskarinski agonisti i antagonisti
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
ID29790A (id) PENGGUNAAN IMIDAZO(1,5-a)-PIRIDO(3,2-e)-PIRAZINON SEBAGAI OBAT
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
ES2174573T3 (es) Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
AP9801307A0 (en) Use of 3-amino-4-hydroxbenzoic acid for treatment of retroviral infections.
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.